AR116666A1 - Compuestos heterocíclicos - Google Patents

Compuestos heterocíclicos

Info

Publication number
AR116666A1
AR116666A1 ARP190102303A ARP190102303A AR116666A1 AR 116666 A1 AR116666 A1 AR 116666A1 AR P190102303 A ARP190102303 A AR P190102303A AR P190102303 A ARP190102303 A AR P190102303A AR 116666 A1 AR116666 A1 AR 116666A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
alkoxy
hydroxy
substituted
Prior art date
Application number
ARP190102303A
Other languages
English (en)
Inventor
Marius Lutz
Bernd Kuhn
Carsten Kroll
Buelent Kocer
Benoit Hornsperger
Zbinden Katrin Groebke
Uwe Grether
Luca Gobbi
Joerg Benz
Charles Bell
Martin Kuratli
Didier Rombach
Martin Ritter
Hans Richter
Fionn Ohara
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR116666A1 publication Critical patent/AR116666A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Reivindicación 1: Compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en la que: (i) X es C-R³; m es 0 ó 1; n se selecciona de 0, 1 y 2; y L se selecciona de -(CH₂)ₚ-, -O-, -OCH₂-, -CH₂OCH₂-, -CF₂CH₂-, -CH₂=CH₂-, -(CR¹⁶R¹⁷)q-CH₂O-, y -CH₂CF₂-; o (ii) X es N; m es 1; n es 1 ó 2; y L es -(CH₂)ₚ- o -CF₂CH₂-, p se selecciona de 1, 2 y 3, q es 0 ó 1, A se selecciona de: (i) arilo C₆₋₁₄ sustituido con R⁴, R⁵ y R⁶, (ii) heteroarilo de 5 a 14 elementos sustituido con R⁷, R⁸ y R⁹, y (iii) heterocicloalquilo de 3 a 14 elementos sustituido con R¹⁰, R¹¹ y R¹², R¹ es hidrógeno o alquilo C₁₋₆, R² se selecciona de hidrógeno, alquilo C₁₋₆ e hidroxi-alquilo C₁₋₆, R³ se selecciona de hidrógeno, halógeno, hidroxi, alcoxi C₁₋₆, alquilo C₁₋₆, y halo-alquilo C₁₋₆, cada uno de R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹ y R¹² se selecciona independientemente de hidrógeno, halógeno, ciano, hidroxi, alquilo C₁₋₆, halo-alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, alcanoilo C₁₋₆, halo-alquil C₁₋₅-CH(OH)-, alcoxi C₁₋₆, halo-alcoxi C₁₋₆, SF₅, CH₃SO₂, cicloalquilo C₃₋₁₀, cicloalquilo C₃₋₁₀ sustituido con R¹³, heterocicloalquilo de 3 a 14 elementos, heterocicloalquilo de 3 a 14 elementos sustituido con R¹⁴ y R¹⁵, heteroarilo de 5- a 14 elementos, arilo C₆₋₁₄, ariloxi C₆₋₁₄, halo-arilo C₆₋₁₄, y halo-ariloxi C₆₋₁₄, cada uno de R¹³, R¹⁴ y R¹⁵ se selecciona independientemente de alquilo C₁₋₆, alcoxi C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, halógeno e hidroxi, y R¹⁶ y R¹⁷, junto con el átomo de carbono al que se encuentran unidos, forman un cicloalquilo C₃₋₁₀.
ARP190102303A 2018-08-13 2019-08-13 Compuestos heterocíclicos AR116666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18188681 2018-08-13

Publications (1)

Publication Number Publication Date
AR116666A1 true AR116666A1 (es) 2021-06-02

Family

ID=63244467

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102303A AR116666A1 (es) 2018-08-13 2019-08-13 Compuestos heterocíclicos

Country Status (22)

Country Link
US (3) US20200308190A1 (es)
EP (1) EP3837263A1 (es)
JP (1) JP2021534139A (es)
KR (1) KR20210045992A (es)
CN (1) CN112867720A (es)
AR (1) AR116666A1 (es)
AU (1) AU2019322538B2 (es)
BR (1) BR112021002298A2 (es)
CA (1) CA3104928A1 (es)
CL (1) CL2021000362A1 (es)
CO (1) CO2021002382A2 (es)
CR (1) CR20210077A (es)
IL (1) IL279173A (es)
MA (1) MA53219A (es)
MX (1) MX2021001433A (es)
PE (1) PE20211089A1 (es)
PH (1) PH12021500013A1 (es)
RU (1) RU2769507C1 (es)
SG (1) SG11202013064WA (es)
TW (1) TWI812770B (es)
UA (1) UA127629C2 (es)
WO (1) WO2020035424A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
EP3717477B1 (en) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG New heterocyclic compounds
CN111566105A (zh) 2018-01-08 2020-08-21 豪夫迈·罗氏有限公司 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CA3104928A1 (en) 2018-08-13 2020-02-20 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AU2020343737A1 (en) * 2019-09-05 2022-03-31 Lunan Pharmaceutical Group Corporation MAGL inhibitor, preparation method therefor and use thereof
US20210094971A1 (en) * 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
CR20220104A (es) 2019-09-12 2022-04-20 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
CR20220116A (es) * 2019-09-23 2022-04-20 Hoffmann La Roche Compuestos heterocíclicos
CA3155724A1 (en) * 2019-09-24 2021-04-01 F. Hoffmann-La Roche Ag Heterocyclic compounds
EP4034538A1 (en) * 2019-09-24 2022-08-03 F. Hoffmann-La Roche AG New heterocyclic monoacylglycerol lipase (magl) inhibitors
KR20220079880A (ko) * 2019-10-07 2022-06-14 디.이. 쇼우 리서치, 엘엘씨 Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴메틸렌 헤테로시클릭 화합물
CA3176113A1 (en) * 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
JP2023539690A (ja) 2020-09-03 2023-09-15 エフ． ホフマン－ラ ロシュ アーゲー 複素環式化合物

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214038A (en) 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
JP5023054B2 (ja) 2005-03-31 2012-09-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としての二環式ピラゾール化合物
EP1896453B1 (en) 2005-06-20 2009-12-02 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
JP2010519171A (ja) 2006-02-17 2010-06-03 メモリー・ファーマシューティカルズ・コーポレイション ５−ｈｔ６受容体親和性を有する化合物
US7872028B2 (en) 2006-04-05 2011-01-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
CN103626766B (zh) 2007-03-12 2017-06-09 细胞内治疗公司 与取代的杂环稠合的γ‑咔啉的合成
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
PE20110574A1 (es) 2008-10-29 2011-08-11 Hoffmann La Roche Derivados de fenilamida y de piridilamida como agonistas de gpbar1
EP2475667A1 (en) 2009-09-10 2012-07-18 F. Hoffmann-La Roche AG Inhibitors of jak
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
WO2013059118A1 (en) 2011-10-19 2013-04-25 The Trustees Of Columbia University In The City Of New York Cyclopropenimine catalyst compositions and processes
CN103958525A (zh) 2011-11-30 2014-07-30 埃科特莱茵药品有限公司 3,7-二取代八氢-2H-吡啶并[4,3-e][1,3]噁嗪-2-酮抗生素
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
KR101653473B1 (ko) 2012-01-06 2016-09-01 어바이드 테라퓨틱스, 인크. 카르바메이트 화합물 및 그의 제조 및 이용 방법
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
BR112015026261A8 (pt) 2013-04-16 2017-12-26 Actelion Pharmaceuticals Ltd Derivados biaromáticos antibacterianos
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
JP6653319B2 (ja) 2015-03-30 2020-02-26 武田薬品工業株式会社 複素環化合物
TW201713641A (zh) 2015-05-13 2017-04-16 賽爾維他股份公司 經取代之喹喏啉衍生物
WO2016185279A1 (en) 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換４−ベンジル及び４−ベンゾイルピペリジン誘導体
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
US10323038B2 (en) 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
JP6832342B2 (ja) 2016-03-31 2021-02-24 武田薬品工業株式会社 複素環化合物
AR108012A1 (es) 2016-03-31 2018-07-04 Takeda Pharmaceuticals Co Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl
TW201806939A (zh) 2016-06-30 2018-03-01 巴塞利亞藥業國際股份有限公司 用於治療增生性障礙之線粒體抑制劑
PE20200340A1 (es) 2017-06-12 2020-02-14 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de vanina
CN111148746B (zh) 2017-09-29 2022-08-05 武田药品工业株式会社 杂环化合物
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
EP3717477B1 (en) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG New heterocyclic compounds
TW201930300A (zh) 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
CN111566105A (zh) 2018-01-08 2020-08-21 豪夫迈·罗氏有限公司 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物
DK3768684T3 (da) 2018-03-22 2023-04-24 Hoffmann La Roche Oxazin-monoacylglycerol-lipase (MAGL)-hæmmere
CA3104928A1 (en) 2018-08-13 2020-02-20 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
SG11202012222TA (en) 2018-08-13 2021-01-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
PE20211871A1 (es) 2018-11-22 2021-09-21 Qilu Regor Therapeutics Inc Agonistas de glp-1r y usos de los mismos
PL3883936T3 (pl) 2018-11-22 2023-11-20 F. Hoffmann-La Roche Ag Nowe związki heterocykliczne
CN113767105A (zh) 2019-04-09 2021-12-07 豪夫迈·罗氏有限公司 作为单酰基甘油脂肪酶(magl)的抑制剂的杂环化合物
AU2020299965A1 (en) 2019-07-03 2022-02-03 F. Hoffmann-La Roche Ag Heterocyclic monoacylglycerol lipase (MAGL) inhibitors
EP3997096A1 (en) 2019-07-09 2022-05-18 F. Hoffmann-La Roche AG New heterocyclic compounds
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
CR20220104A (es) 2019-09-12 2022-04-20 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
WO2021048241A1 (en) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag Radiolabeled compounds
CR20220116A (es) 2019-09-23 2022-04-20 Hoffmann La Roche Compuestos heterocíclicos
JP2022549306A (ja) 2019-09-24 2022-11-24 エフ．ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ（ｍａｇｌ）の蛍光プローブ
EP4034538A1 (en) 2019-09-24 2022-08-03 F. Hoffmann-La Roche AG New heterocyclic monoacylglycerol lipase (magl) inhibitors
CA3155724A1 (en) 2019-09-24 2021-04-01 F. Hoffmann-La Roche Ag Heterocyclic compounds
JP2023539690A (ja) 2020-09-03 2023-09-15 エフ． ホフマン－ラ ロシュ アーゲー 複素環式化合物

Also Published As

Publication number Publication date
CR20210077A (es) 2021-03-11
AU2019322538A1 (en) 2021-01-07
UA127629C2 (uk) 2023-11-08
CO2021002382A2 (es) 2021-03-08
US20200308190A1 (en) 2020-10-01
US20240150373A1 (en) 2024-05-09
PH12021500013A1 (en) 2021-09-13
MA53219A (fr) 2021-11-17
TWI812770B (zh) 2023-08-21
SG11202013064WA (en) 2021-01-28
TW202021970A (zh) 2020-06-16
PE20211089A1 (es) 2021-06-14
JP2021534139A (ja) 2021-12-09
CA3104928A1 (en) 2020-02-20
US11802133B2 (en) 2023-10-31
BR112021002298A2 (pt) 2021-05-04
RU2769507C1 (ru) 2022-04-01
CL2021000362A1 (es) 2021-07-09
EP3837263A1 (en) 2021-06-23
MX2021001433A (es) 2021-04-12
US20230050901A1 (en) 2023-02-16
AU2019322538B2 (en) 2021-09-30
IL279173A (en) 2021-01-31
KR20210045992A (ko) 2021-04-27
CN112867720A (zh) 2021-05-28
WO2020035424A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
AR116666A1 (es) Compuestos heterocíclicos
AR123089A2 (es) Compuesto de piridinona
AR092742A1 (es) Piridinonas antifibroticas
AR112682A1 (es) Compuestos herbicidas
AR111241A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AR096837A1 (es) Heterociclos tricíclicos como inhibidores de proteínas bet
AR103182A1 (es) Inmunomoduladores
AR105392A1 (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
AR098721A1 (es) Inhibidores de biarilo de tirosina quinasa de bruton
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR111279A1 (es) Derivados heterocíclicos útiles como inhibidores duales de atx / ca
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR093339A1 (es) Analogos de spliceostatina y metodos para su preparacion
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR119943A1 (es) Compuestos heterocíclicos
AR110405A1 (es) Compuestos
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR095326A1 (es) Heterociclos tricíclicos como inhibidores de la proteína bet
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
AR092347A1 (es) Derivados de azaindol
AR102851A1 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR112907A1 (es) Pirazoles inhibidores de monoacilglicerol lipasa (magl)
AR101479A1 (es) Derivados de 6-alquinil-piridina